In summary, our results indicate that ATP1B3 is upregulated and promote the tumorigenicity of HCC, and it is also an independent prognostic biomarker for the diagnosis of HCC with a potential immunomodulatory role, providing a novel prognostic biomarker and potential therapeutic target for HCC. Here, ATP1B3 is linked to hepatocellular carcinoma.